AmericanPeptide
Catalog/SLU-PP-332

SLU-PP-332

Also known as SLU PP 332

A synthetic small-molecule pan-ERR agonist studied as an “exercise mimetic” — not a peptide.

Research refreshed

Overview

SLU-PP-332 is a synthetic small molecule — not a peptide — that activates all three estrogen-related receptors (ERRα, ERRβ, ERRγ), the orphan nuclear receptors that control oxidative metabolism and mitochondrial biogenesis. It is studied as an “exercise mimetic”: in preclinical work it increased a type of muscle fiber and oxidative metabolism and reduced fat mass in mice without changes in food intake or activity. It is an early research compound with no human data and no approval.

Background

SLU-PP-332 came out of medicinal-chemistry work (Burris and colleagues) to find a direct agonist of the estrogen-related receptors, which sit downstream of PGC-1α and govern how cells build mitochondria and burn fat. Activating that program pharmacologically is the idea behind an “exercise mimetic” — reproducing some transcriptional effects of endurance exercise without the exercise.

In mouse studies the compound raised oxidative (fatigue-resistant) muscle fiber content and energy expenditure and reduced fat mass and diet-induced obesity. All of this is preclinical: there is no clinical trial, no safety data in humans, and it is a research chemical rather than a peptide or an approved drug.

Mechanism

Pan-ERR (ERRα/β/γ) agonism, upregulating the PGC-1α/ERR transcriptional program for mitochondrial biogenesis, fatty-acid oxidation, and oxidative muscle metabolism.

Key research findings

  • Pan-ERR agonist — directly activates ERRα/β/γ, the receptors downstream of PGC-1α that drive mitochondrial and oxidative metabolism.
  • Exercise-mimetic phenotype — increased oxidative muscle fiber and energy expenditure in mice.
  • Fat-mass reduction — reduced diet-induced obesity in mice without changes in food intake.
  • Small molecule, preclinical — not a peptide; no human data and not FDA-approved.

How SLU-PP-332 is made

Behind every vial of SLU-PP-332 is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how SLU-PP-332, specifically, is brought into being.

  1. On paper first

    SLU-PP-332 begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.

  2. Built residue by residue

    SLU-PP-332 is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later. It also carries fatty-acid acylation, an extra step beyond a plain chain that adds both capability and cost.

  3. Purity is won here

    The crude mixture — SLU-PP-332 plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.

  4. Proven, then protected

    A real batch of SLU-PP-332 proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of SLU-PP-332 — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.

Walk the full synthesis pipeline

Handling, storage & why purity is hard

Not a peptide — a synthetic small molecule made by conventional organic synthesis. Its purity and identity are an organic-chemistry question answered by HPLC and NMR/mass spectrometry, not by peptide solid-phase synthesis or a peptide-style certificate. Vendor material described with a peptide CoA is a red flag that the wrong analysis was run.

Standard synthesisSmall molecule
Storage
As a small molecule rather than a peptide, store per the compound’s own stability — typically cool, dry, and light-protected; reconstitution depends on its solvent, not on peptide practice.
Handling
Handle by organic-chemistry practice: dissolve in the appropriate solvent, and verify identity and purity by HPLC with NMR or mass spectrometry rather than a peptide-style certificate.

Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.

How peptides are made — the full pipeline

Research areas

  • Mitochondrial biogenesis
  • Obesity (preclinical)
  • Exercise mimetic research
  • Oxidative metabolism

Research-area guides

Frequently asked questions

What is SLU-PP-332?+

A synthetic small-molecule agonist of the estrogen-related receptors (ERRα/β/γ), studied as an exercise mimetic that boosts oxidative metabolism in preclinical models. It is not a peptide.

Why is it called an exercise mimetic?+

It activates the PGC-1α/ERR transcriptional program that endurance exercise normally engages — mitochondrial biogenesis and fat oxidation — pharmacologically rather than through exercise.

Is there human data?+

No. The published work is in mice; there is no clinical trial or human safety data.

Is it approved?+

No — it is an early research compound, not FDA-approved. This page is a research and educational reference.

Related peptides

Peptide Agent

Ask the Agent about SLU-PP-332

Dosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.